Page 53 - MEMORIA ANUAL 2018 SEHH-FEHH

PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
Presentaciones orales en congresos internacionales
MEMORIA ANUAL 2018 SOCIEDAD ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA
FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA
• Misiewicz-Krzeminska I, Corchete L, Isidro I, Prieto T, Gutiérrez V, Rojas E, et al. Expression of proteins in CD138+ plasma cells predicts prognosis in newly diagnosed multiple myeloma patients treated with vrd regimen. 23rd Congress of the European Hematology Association (EHA). Stockholm, Sweden, June 14-17, 2018.
• Mgraw KI, Cheng CH, Chen A, Hou HA, Genovese G, Cluzeau T, Pellagatti A, Przychodzen B, Mallo M, Arenillas L, Mohamedali A, Ades L, Sallman D, Padron E, Sokol L, Brest C, Boultwood, Ebert B, Solé F, Fenaux P, Mufti G, Maciejewski J, Kanetsky PA. SNP-array meta-analysis identification of innate immune susceptibility loci linked to non-del(5q) Myelodysplastic Syndromes predisposition. Blood. 2018;132:468. doi: https://doi.org/10.1182/ blood-2018-99-119428. 60th American Society of Hematology (ASH) Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• López Cadenas F, Lumbreras E, Xicoy B, Sánchez-García J, Fenaux P, Coll R, Slama B, Hernández-Rivas JA, Thepot S, Bernal T, Arrizabalaga B, Guerci A, Sanz G, Bargay J, Amigo ML, de Paz R, Giagounidis A, Platzbecker U, Nomdedeu B, Jourdan E, Götze KS, Arar A, Hernández-Rivas JM, Del Cañizo C, Díez-Campelo M. Phase 3 Study of Lenalido- mide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Pre- liminary Blinded Analysis of the European Sintra-REV Trial. Blood. 2018;132:468. doi: https://doi.org/10.1182/ blood-2018-99-119430. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Jiménez Ubieto A, Paiva B, Martínez-López J, Rosiñol L, Cedena Romero MT, Calasanz MJ, Puig N, García-Sanz R, Gutiérrez NC, Martín-Ramos ML, Oriol A, González Medina J, Alonso Fernández R, Blanchard J, Ríos R, Martín J, Martínez Martínez R, Sarra J, Hernández MT, De La Rubia J, Krsnik I, Moraleda JM, Palomera L, Mateos MV, San-Mi- guel JF, Bladé J, Lahuerta JJ. Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial. Blood. 2018;132:474. doi: https://doi.org/10.1182/blood-2018-99-115050. 60th ASH Annual Meeting and Exposition. San Di- ego, 1-4 de diciembre de 2018.
• Rosiñol Dachs L, Oriol A, Teruel AI, López de la Guía A, Blanchard MJ, Jarque I, Granell M, Sampol A, Palomera L, González-Montes Y, Bengoechea E, Martínez-Martínez R, Hernández MT, De Arriba F, Martín-Ramos ML, Gutiérrez NC, Ci- beira MT, Mateos MV, Martínez-López J, Alegre A, Lahuerta JJ, San-Miguel JF, Bladé. VTD (Bortezomib/Thalidomide/Dexa- methasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. Blood. 2018;132:126. doi: https://doi.org/10.1182/blood-2018-99-111924. 60th ASH Annual Meet- ing and Exposition. San Diego, 1-4 de diciembre de 2018.
• Medina A, Jiménez C, Sarasquete ME, Puig N, Balanzategui A, Alcoceba M, González De La Calle V, García-Álvarez M, Prieto-Conde I, Chillón C, Ocio EM, Gutiérrez NC, Mateos MV, Martínez-López J, Lahuerta JJ, San-Miguel JF, González M, García-Sanz R. VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. Blood. 2018;132:4446. doi: https://doi.org/10.1182/blood-2018-99-114627. 60th ASH Annual Meeting and Ex- position. San Diego, 1-4 de diciembre de 2018.
• Rodríguez Otero P, Mateos MV, Martínez López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González-Montes Y, Pérez De Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, De Arriba F, Cedena Romero MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF. Biomark- ers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor. Blood. 2018;132:4503. doi: https://doi.org/10.1182/ blood-2018-99-117431. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Rosiñol Dachs L, Hebraud B, Oriol A, Colin AL, Ríos R, Hulin C, Blanchard MJ, Caillot D, Sureda A, Hernández MT, Arnulf B, Mateos MV, Macro M, San-Miguel JF, Belhadj K, Lahuerta JJ, Chen G, Garelik MB, Bladé J, Moreau P, Attal
53